Shenzhen Bioeasy Biotechnology Co. Ltd.
Shenzhen Bioeasy Biotechnology Co., Ltd., together with its subsidiaries, provides rapid food testing reagents and instruments in China and internationally. The company offers test kits, including veterinary, melamine, mycotoxin, pesticide, adulteration, ATP, vitamin, and others; equipment, such as incubator, reader, suitcase lab, automatic pressers, and others; and materials comprising pretreatm… Read more
Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) - Total Assets
Latest total assets as of September 2025: CN¥1.48 Billion CNY
Based on the latest financial reports, Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) holds total assets worth CN¥1.48 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shenzhen Bioeasy Biotechnology Co. Ltd. - Total Assets Trend (2016–2024)
This chart illustrates how Shenzhen Bioeasy Biotechnology Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shenzhen Bioeasy Biotechnology Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Shenzhen Bioeasy Biotechnology Co. Ltd.'s total assets of CN¥1.48 Billion consist of 51.6% current assets and 48.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 20.1% |
| Accounts Receivable | CN¥99.91 Million | 6.9% |
| Inventory | CN¥40.43 Million | 2.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥39.24 Million | 2.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Shenzhen Bioeasy Biotechnology Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shenzhen Bioeasy Biotechnology Co. Ltd.'s current assets represent 51.6% of total assets in 2024, a decrease from 81.9% in 2016.
- Cash Position: Cash and equivalents constituted 20.1% of total assets in 2024, down from 56.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 6.9% of total assets.
Shenzhen Bioeasy Biotechnology Co. Ltd. Competitors by Total Assets
Key competitors of Shenzhen Bioeasy Biotechnology Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Shenzhen Bioeasy Biotechnology Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shenzhen Bioeasy Biotechnology Co. Ltd. generates 0.15x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Shenzhen Bioeasy Biotechnology Co. Ltd. generates $ 1.17 in net profit.
Shenzhen Bioeasy Biotechnology Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.16 | 5.17 | 6.73 |
| Quick Ratio | 4.77 | 4.90 | 5.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥625.07 Million | CN¥ 591.60 Million | CN¥ 448.01 Million |
Shenzhen Bioeasy Biotechnology Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Shenzhen Bioeasy Biotechnology Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.20 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 7.4% |
| Total Assets | CN¥1.46 Billion |
| Market Capitalization | $213.89 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shenzhen Bioeasy Biotechnology Co. Ltd.'s assets below their book value (0.15 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shenzhen Bioeasy Biotechnology Co. Ltd.'s assets grew by 7.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shenzhen Bioeasy Biotechnology Co. Ltd. (2016–2024)
The table below shows the annual total assets of Shenzhen Bioeasy Biotechnology Co. Ltd. from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.46 Billion | +7.43% |
| 2023-12-31 | CN¥1.36 Billion | +5.76% |
| 2022-12-31 | CN¥1.28 Billion | +11.27% |
| 2021-12-31 | CN¥1.15 Billion | +76.53% |
| 2020-12-31 | CN¥652.89 Million | +5.36% |
| 2019-12-31 | CN¥619.67 Million | +108.76% |
| 2018-12-31 | CN¥296.83 Million | +70.79% |
| 2017-12-31 | CN¥173.80 Million | +41.22% |
| 2016-12-31 | CN¥123.07 Million | -- |